Investigations of Walgreens Boots Alliance

Are you a former employee of Walgreens Boots Alliance, Inc. (WBA) and own stock in the company? Robbins LLP is investigating breaches of fiduciary duty by the officers and board of directors of WBA.

Walgreens Boots Alliance, Inc. (WBA) Accused of Multiple FCA Violations

From January 2006 until December 2017, Walgreens Boots Alliance, inc.(WBA) violated the FCA by systematically under-reporting the days of supply for insulin pens in claims submitted to federal programs. The Company’s full-box-only insulin pen dispensing practice frequently resulted in third party payors denying Walgreens’ insulin pen claims because the days of supply exceeded the payor’s limits. When claims were denied, Walgreens falsely under-reported the days of supply for the box of pens as 30-days, even though the box of pens was actually a 65-day supply, in order to match the payor’s limitations. Consequently, federal programs paid far more to Walgreens for insulin than beneficiaries actually needed. The Company also violated the FCA by failing to disclose the discount drug price it offered the public through its Prescription Savings Club program (“PSC program”) and submitting false claims for reimbursement that overcharged Medicaid for those drugs. As a result of its fraudulent behavior, on January 2, 2019, Walgreens announced it would pay $269 million to settle civil fraud allegations, $209.2 million to resolve claims it improperly billed Medicare and other federal programs, and $60 million for overcharging Medicaid through its PSC program.

Send us a message for more information.

Protect your investments.

Sign up for free investment monitoring.

Stock Watch members receive free investment monitoring and notifications.  

Leave your details to get started

"*" indicates required fields

Ticker + Amount
This field is for validation purposes and should be left unchanged.

Skip to content